Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Traumadornase: a Prospective, Randomized Multicenter, Double Blind Clinical Trial Comparing Inhaled Dornase Alfa and Its Placebo to Reduce the Incidence of Moderate to Severe ARDS in Ventilated Trauma Patients in the Intensive Care Unit

Next Previous
X
Search
Trial Profile

Traumadornase: a Prospective, Randomized Multicenter, Double Blind Clinical Trial Comparing Inhaled Dornase Alfa and Its Placebo to Reduce the Incidence of Moderate to Severe ARDS in Ventilated Trauma Patients in the Intensive Care Unit

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dornase alfa (Primary)
  • Indications Adult respiratory distress syndrome; Wounds and injuries
  • Focus Therapeutic Use
  • Acronyms TRAUMADORNASE

    • Most Recent Events

    • 29 Aug 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2027.
    • 29 Aug 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2027.
    • 07 Jul 2022 Planned End Date changed from 1 Sep 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top